SC-01:   IgE Therapeutics has analyzed the effect of the IgE protein and gene in biological systems. The drug lead, SC-01 is a biological peptide that causes down-regulation of IgE production by IgE-producing B-cells and plasma cells. SC-01 prevents IgE sensitization to mast cells and activation by allergens.

SC-02:   The drug lead, SC-02 is a biological peptide inserted into a protein scaffold that causes production of anti-IgE. The actively produced anti-IgE neutralizes existing IgE and protect mast cells from activation by IgE and allergens.